Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure

Name: Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure
Published: 2019
License: Public Domain

ModernaTX, Inc. · 2019

ClinicalTrials.gov · Datasets · License: Public Domain · 2019

Open Source ↗

human metapneumovirus and human parainfluenza infection, modernatx, mrna-1653, human metapneumovirus, human parainfluenza, human parainfluenza vaccine, virus diseases, rna virus infections, paramyxoviridae infections, mononegavirales infections, interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure

Related documents